News stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fluidigm earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.7382061134891 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
Best Medical Stocks To Invest In Right Now: PVH Corp.(PVH)
Advisors’ Opinion:
- [By Lisa Levin]
Some of the stocks that may grab investor focus today are:
Wall Street expects Dollar General Corporation (NYSE: DG) to report quarterly earnings at $1.4 per share on revenue of $6.20 billion before the opening bell. Dollar General shares rose 0.13 percent to $96.65 in after-hours trading.
Analysts expect Costco Wholesale Corporation (NASDAQ: COST) to post quarterly earnings at $1.67 per share on revenue of $31.51 billion after the closing bell. Costco shares rose 0.46 percent to $200.55 in after-hours trading.
Crispr Therapeutics AG (NASDAQ: CRSP) disclosed that the FDA has placed a clinical hold on IND for CTX001 sickle cell disease treatment. Crispr Therapeutics shares dropped 14.39 percent to $63.00 in the after-hours trading session.
Before the markets open, Tech Data Corporation (NASDAQ: TECD) is projected to report quarterly earnings at $1.46 per share on revenue of $8.13 billion. Tech Data shares gained 1.52 percent to close at $82.40 on Wednesday.
Analysts are expecting Dollar Tree, Inc. (NASDAQ: DLTR) to have earned $1.23 per share on revenue of $5.56 billion in the latest quarter. Dollar Tree will release earnings before the markets open. Dollar Tree shares gained 0.66 percent to $96.99 in after-hours trading.
PVH Corp (NYSE: PVH) reported stronger-than-expected results for its first quarter and raised its earnings guidance for the year. PVH shares rose 0.37 percent to close at $155.50 on Wednesday.Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Max Byerly]
Systematic Financial Management LP decreased its stake in PVH Corp (NYSE:PVH) by 32.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,498 shares of the textile maker’s stock after selling 52,310 shares during the period. Systematic Financial Management LP owned approximately 0.14% of PVH worth $16,244,000 as of its most recent SEC filing.
- [By Max Byerly]
State of Alaska Department of Revenue grew its holdings in PVH Corp (NYSE:PVH) by 14.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 22,780 shares of the textile maker’s stock after acquiring an additional 2,910 shares during the period. State of Alaska Department of Revenue’s holdings in PVH were worth $3,409,000 at the end of the most recent reporting period.
- [By Joseph Griffin]
Dynamic Technology Lab Private Ltd grew its holdings in PVH Corp (NYSE:PVH) by 60.6% during the first quarter, HoldingsChannel.com reports. The firm owned 3,078 shares of the textile maker’s stock after acquiring an additional 1,162 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in PVH were worth $467,000 at the end of the most recent quarter.
Best Medical Stocks To Invest In Right Now: Anixter International Inc.(AXE)
Advisors’ Opinion:
- [By Stephan Byrd]
TheStreet upgraded shares of Anixter International (NYSE:AXE) from a c+ rating to a b rating in a report issued on Wednesday morning.
Several other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Anixter International from a sell rating to a strong sell rating in a research note on Tuesday. Zacks Investment Research downgraded shares of Anixter International from a strong-buy rating to a hold rating in a research note on Tuesday, September 25th. Finally, Longbow Research upgraded shares of Anixter International from a neutral rating to a buy rating in a research note on Friday, July 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Anixter International has a consensus rating of Hold and an average target price of $85.50.
- [By Max Byerly]
TheStreet upgraded shares of Anixter International (NYSE:AXE) from a c+ rating to a b- rating in a research report released on Wednesday morning.
Several other brokerages have also recently issued reports on AXE. Zacks Investment Research raised Anixter International from a sell rating to a hold rating in a report on Monday, December 3rd. ValuEngine downgraded Anixter International from a sell rating to a strong sell rating in a research report on Wednesday, January 30th. Finally, Wells Fargo & Co cut their target price on Anixter International from $70.00 to $60.00 and set a market perform rating on the stock in a research report on Friday, December 21st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $70.50.
- [By Shane Hupp]
Strs Ohio boosted its position in Anixter International Inc. (NYSE:AXE) by 15.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 18,700 shares of the technology company’s stock after acquiring an additional 2,500 shares during the period. Strs Ohio’s holdings in Anixter International were worth $1,183,000 as of its most recent SEC filing.
Best Medical Stocks To Invest In Right Now: Concert Pharmaceuticals, Inc.(CNCE)
Advisors’ Opinion:
- [By Stephan Byrd]
Teachers Advisors LLC boosted its position in Concert Pharmaceuticals (NASDAQ:CNCE) by 293.9% during the fourth quarter, Holdings Channel reports. The fund owned 135,399 shares of the biotechnology company’s stock after purchasing an additional 101,026 shares during the quarter. Teachers Advisors LLC’s holdings in Concert Pharmaceuticals were worth $3,503,000 at the end of the most recent quarter.
- [By Max Byerly]
Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) have earned a consensus rating of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.33.
- [By Max Byerly]
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) have been given an average rating of “Buy” by the nine research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $27.80.
- [By Stephan Byrd]
Media coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.0633525271097 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
- [By Stephan Byrd]
Concert Pharmaceuticals (NASDAQ:CNCE) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Thursday.
Best Medical Stocks To Invest In Right Now: Atlantic Power Corporation(AT)
Advisors’ Opinion:
- [By Stephan Byrd]
AWARE (CURRENCY:AT) traded up 2.3% against the US dollar during the 1 day period ending at 18:00 PM E.T. on September 10th. AWARE has a market capitalization of $0.00 and $101,493.00 worth of AWARE was traded on exchanges in the last day. In the last seven days, AWARE has traded 22.2% lower against the US dollar. One AWARE token can currently be bought for about $0.0038 or 0.00000060 BTC on popular cryptocurrency exchanges.
- [By Ethan Ryder]
ABCC Token (CURRENCY:AT) traded flat against the U.S. dollar during the 24 hour period ending at 20:00 PM ET on September 23rd. One ABCC Token token can currently be purchased for $0.0000 or 0.00000000 BTC on major cryptocurrency exchanges. ABCC Token has a market cap of $0.00 and $0.00 worth of ABCC Token was traded on exchanges in the last 24 hours. Over the last week, ABCC Token has traded flat against the U.S. dollar.
- [By Logan Wallace]
ABCC Token (CURRENCY:AT) traded flat against the US dollar during the 24 hour period ending at 7:00 AM E.T. on October 2nd. ABCC Token has a total market capitalization of $0.00 and approximately $0.00 worth of ABCC Token was traded on exchanges in the last 24 hours. In the last week, ABCC Token has traded flat against the US dollar. One ABCC Token token can now be bought for approximately $0.0000 or 0.00000000 BTC on cryptocurrency exchanges.
- [By Logan Wallace]
Media stories about Atlantic Power (NYSE:AT) (TSE:ATP) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atlantic Power earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the utilities provider an impact score of 47.4126329966204 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Best Medical Stocks To Invest In Right Now: Changyou.com Limited(CYOU)
Advisors’ Opinion:
- [By Ethan Ryder]
Shenzhen Xunlei Networking Technologies (NASDAQ: XNET) and Changyou (NASDAQ:CYOU) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
- [By Keith Noonan, George Budwell, and Maxx Chatsko]
We asked three Motley Fool contributors to profile a stock that they believe is trading at a substantial discount and has what it takes to be a long-term winner. Read on to see why they identified A.O. Smith (NYSE:AOS), GlaxoSmithKline (NYSE:GSK), and Changyou.com (NASDAQ:CYOU) as top value stocks to buy this September.
- [By Motley Fool Transcribers]
ChangYou.com (NASDAQ:CYOU)Q4 2018 Earnings Conference CallFeb. 01, 2019, 12:30 p.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers
Changyou.com Limited (NASDAQ: CYOU) fell 27.5 percent to $21.35 in pre-market trading.
Flex Ltd. (NASDAQ: FLEX) fell 19.7 percent to $13.36 in pre-market trading after a mixed fourth quarter report.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares fell 10.5 percent to $7.15 in pre-market trading following mixed Q1 results.
Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) fell 8.1 percent to $2.16 in pre-market trading.
LogMeIn Inc (NASDAQ: LOGM) fell 8 percent to $110.05 in pre-market trading. LogMeIn reported upbeat earnings for its first quarter, but issued weak second quarter and FY18 earning guidance.
United States Steel Corporation (NYSE: X) fell 6.2 percent to $35.36 in pre-market trading following Q1 results.
Deutsche Bank Aktiengesellschaft (NYSE: DB) fell 5 percent to $13.63 in pre-market trading.
Sony Corporation (NYSE: SNE) shares fell 4.3 percent to $48.00 in pre-market trading after reporting Q4 results.
Colgate-Palmolive Company (NYSE: CL) shares fell 4 percent to $64.00 in pre-market trading. Colgate-Palmolive posted upbeat Q1 earnings, while sales missed estimates - [By Rick Munarriz]
Just one segment of the Chinese online advertising, search, and gaming specialist mustered a year-over-year gain for both the quarter and all of 2018. But investors seem to prefer the sum-of-the-parts coverage that Sohu provides. Spun-off subsidiaries Sogou (NYSE:SOGO) and Changyou.com (NASDAQ:CYOU) — representing Sohu’s search and gaming operations, respectively — were inching lower hours into Friday’s trading day as Sohu shares were drifting higher.
Best Medical Stocks To Invest In Right Now: CSG Systems International Inc.(CSGS)
Advisors’ Opinion:
- [By Joseph Griffin]
News articles about CSG Systems International (NASDAQ:CSGS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CSG Systems International earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 46.8716525043945 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
- [By Ethan Ryder]
B. Riley began coverage on shares of CSG Systems International (NASDAQ:CSGS) in a report released on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $51.00 target price on the technology company’s stock.
- [By Logan Wallace]
Get a free copy of the Zacks research report on CSG Systems International (CSGS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com